Upcoming EventsMore >>
There are currently no events scheduled.
Recent NewsMore >>
DateTitle 
09/17/14Amgen Foundation Commits €2 Million to Support Science Teachers Across Europe
Amgen Teach Equips European Secondary School Teachers to Increase Students’ Scientific Literacy and Interest in Scientific Careers Launching in September 2014 in Austria, Belgium, Czech, France, Germany, Ireland, Italy, Poland, Spain and Turkey THOUSAND OAKS, Calif. and BRUSSELS (Sept. 17, 2014) – The Amgen Foundation, in collaboration with European Schoolnet, has launched Amgen Teach, a three-year professional development initiative, designed to further inspire and engage young people’s inte... 
Printer Friendly Version
09/15/14Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis
Data Presented at the American Society of Bone and Mineral Research 2014 Annual Meeting THOUSAND OAKS, Calif., Sept. 15, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a new exploratory analysis of the open-label extension study of the pivotal Phase 3 fracture trial, which found that treatment with Prolia® (denosumab) for eight years enabled a substantial proportion of women with osteoporosis to achieve non-osteoporotic T-scores (>-2.5) at the lumbar spin... 
Printer Friendly Version
09/15/14New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density
Romosozumab Currently in Phase 3 Clinical Development, Pivotal Data Expected in 2016 THOUSAND OAKS, Calif. and BRUSSELS, Sept. 15, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels:UCB) today announced results from several exploratory analyses of the Phase 2 study evaluating romosozumab in postmenopausal women with low bone mineral density (BMD). Romosozumab is an investigational bone-forming agent that is designed to work by inhibiting the protein sclerostin, thereby incr... 
Printer Friendly Version
09/14/14Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure
Analysis From SHIFT Study Shows Ivabradine Reduced Cardiovascular Death or Hospitalization for Worsening Heart Failure Independent of Baseline Blood Pressure With Similar Safety Profile Across Groups THOUSAND OAKS, Calif., Sept. 14, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annu... 
Printer Friendly Version
What's New
08/07/14
Download Documentation Investor Insights Newsletter - Q2 2014
07/29/14
Download Documentation Q2 2014 Financial Results
Investor Insights Newsletters
DateTitle
08/07/14
Download Documentation Investor Insights Newsletter - Q2 2014
04/30/14
Download Documentation Investor Insights Newsletter - Q1 2014
02/11/14
Download Documentation Investor Insights Newsletter - Q4 2013
10/31/13
Download Documentation Investor Insights Newsletter - Q3 2013

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.